Fulcrum Therapeutics Inc (NASDAQ: FULC) kicked off on Friday, down -0.50% from the previous trading day, before settling in for the closing price of $3.98. Over the past 52 weeks, FULC has traded in a range of $2.86-$13.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -1.37% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 90.67%. With a float of $45.46 million, this company’s outstanding shares have now reached $53.94 million.
In an organization with 76 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.44%, operating margin of -37.66%, and the pretax margin is -22.15%.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 15.71%, while institutional ownership is 91.13%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 90.67% per share during the next fiscal year.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Take a look at Fulcrum Therapeutics Inc’s (FULC) current performance indicators. Last quarter, stock had a quick ratio of 18.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.61 million. That was better than the volume of 0.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 7.86%. Additionally, its Average True Range was 0.33.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 15.63%, which indicates a significant increase from 4.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.83% in the past 14 days, which was lower than the 166.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.98, while its 200-day Moving Average is $6.09. However, in the short run, Fulcrum Therapeutics Inc’s stock first resistance to watch stands at $4.06. Second resistance stands at $4.16. The third major resistance level sits at $4.24. If the price goes on to break the first support level at $3.88, it is likely to go to the next support level at $3.80. The third support level lies at $3.70 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
The company with the Market Capitalisation of 213.60 million has total of 53,939K Shares Outstanding. Its annual sales at the moment are 2,810 K in contrast with the sum of -97,340 K annual income. Company’s last quarter sales were recorded 80,000 K and last quarter income was 55,410 K.
